CV9201 is an RNActive®-based cancer immunotherapy encoding five NSCLC-antigens: NY-ESO-1, melanoma antigen family C1/C2, survivin, and the oncofetal antigen 5T4. The gene discussed is MAGEC1; the disease is cancer.